Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Non-Segmental Vitiligo
NCT04927975Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in Vitiligo (5 arms), sponsored by AbbVie Inc. Primary endpoint: Percent Change From Baseline in Facial-Vitiligo Area Scoring Index at Week 24. Started Jun 2021; status: completed.
02
Drugs
upadacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT04927975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927975.